Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Blood test detects more cancers when added to standard screening

A single blood draw that screens for more than 50 cancers substantially increased cancer detection when added to standard screening, identifying cancers that otherwise might have gone undetected until later stages, according to a new study from the Oregon Health & Science University Knight Cancer Institute.

22 Sep 2026

Study defines early-onset cirrhosis caused by fatty liver disease

Researchers at University of California San Diego School of Medicine have published the first study to define early-onset cirrhosis caused by metabolic dysfunction-associated steatotic liver disease (MASLD), a condition known as fatty liver disease.

16 Sep 2026

New integrated framework advances precision surgery for liver cancer

Hepatocellular carcinoma is the sixth most common malignancy and the third leading cause of cancer-related death globally.

9 Sep 2026

Alcohol-related liver cancer deaths were falling. Then the trend reversed during the COVID-19 pandemic

A global analysis of GBD 2023 data found that alcohol-attributable liver cancer mortality increased modestly from 1990 to 2023, while mortality from alcohol-attributable cirrhosis, alcoholic cardiomyopathy, and alcohol use disorders declined. Liver cancer mortality shifted from a pre-pandemic decline to an increase during 2020–2023, particularly among women, although the researchers cautioned that the ecological analysis cannot establish that pandemic-related changes caused the reversal.

1 Sep 2026

NIH grants support research on whether PFAS exposure increases risk of liver and endometrial cancers

Researchers at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center have received two grants from the National Institutes of Health (NIH) totaling $7.5 million to study whether exposure to per- and polyfluoroalkyl substances (PFAS), the synthetic compounds known as "forever chemicals," increases the risk of liver cancer and endometrial cancer.

25 Aug 2026

A striking immune cell pattern emerges around a person’s 100th birthday

Single-cell immune profiling found that CD4 cytotoxic T lymphocytes become more abundant around age 100, showing stepwise differentiation and substantial clonal expansion. Ex vivo experiments also revealed cytokine plasticity within individual clones, supporting the hypothesis that these cells adapt to persistent antigens during healthy aging, although their direct role in longevity remains unproven.

23 Aug 2026

Combination therapy overcomes ferroptosis resistance in β-catenin-mutant hepatocellular carcinoma

The aberrant activation of the mTOR pathway and its crosstalk with other signaling cascades represent key drivers of hepatocellular carcinoma (HCC) progression. mTOR-mediated ferroptosis suppression has been implicated in HCC resistance to chemotherapy.

7 Aug 2026

Piezo ion channels: Key regulators of digestive health and disease

Mechanosensitive Piezo ion channels, particularly Piezo1 and Piezo2, are gaining recognition as central regulators of digestive system physiology and disease.

7 Aug 2026

Daily tomatoes lowered a key marker of liver fat in MASLD trial

An exploratory randomized trial found that 200 g of raw tomatoes plus 50 g of tomato sauce daily for six weeks produced a greater reduction in CAP-defined hepatic steatosis than a tomato-free diet in adults with MASLD. The improvement occurred without major weight or metabolic changes, but larger and longer trials are needed to confirm its clinical significance.

2 Aug 2026

AI-powered blood test detects liver cancer across distinct populations

Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence (AI)-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and also uncovered the underlying biological signals that make the test effective.

31 Jul 2026

Occult hepatitis B mutations drive liver cancer growth via Akt mTOR pathway

Occult hepatitis B virus (OBI) infection presents a significant global health challenge, notoriously flying under the radar of standard viral screening while relentlessly driving the pathogenesis of hepatocellular carcinoma (HCC).

22 Jul 2026

Study reveals sex-based protein differences across lung cancer types

Biological sex factors into cancer in ways you might not expect. In lung cancer, a form called squamous cell carcinoma disproportionately affects males while adenocarcinoma occurs more frequently in females.

21 Jul 2026

Study tests chronotype’s liver link and finds no significant association

Researchers found no significant association between chronotype and FibroScan-derived liver fat or stiffness in 119 medication-naïve adults with overweight or obesity. The exploratory findings cannot exclude smaller effects, particularly for fibrosis, and require confirmation in larger longitudinal studies.

21 Jul 2026

Study reveals mechanism underlying HBV-induced liver inflammation

Chronic hepatitis B virus (HBV) infection remains a major cause of global liver morbidity, leading to progressive necroinflammation that often culminates in cirrhosis and hepatocellular carcinoma.

17 Jul 2026

AI model predicts effective immunotherapy combinations for liver cancer

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on.

15 Jul 2026

Integrating gene signatures and multi omics improves liver cancer treatment

Hepatocellular carcinoma (HCC) remains highly fatal due to late diagnosis and scarce early biomarkers.

14 Jul 2026

Microbiome science merges with oncology for better cancer treatments

Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to evade immune surveillance and resist conventional therapies.

7 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026

Experts reframe steatotic liver disease as a dynamic continuum

The classification of steatotic liver disease (SLD) is undergoing a major conceptual transformation. In a recent article published in eGastroenterology, Dr. Chen, Dr. Horn, and Prof. Tacke from Charité - Universitätsmedizin Berlin argue that metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD) should not be regarded as rigid diagnostic categories, but rather as interconnected and evolving disease trajectories.

30 Jun 2026

Altering gut microbes could improve immunotherapy responses in liver cancer

Immune checkpoint blockade (ICB) has reshaped the treatment landscape for advanced hepatocellular carcinoma (HCC), offering new hope where few options existed.

30 Jun 2026